Norsk Titanium Announces Strategic Investment from Rose Park Advisors’ Disruptive Innovation Fund
Norsk Titanium, the metal additive manufacturing pioneer, today announced it has closed on a significant investment from Rose Park Advisors’ Disruptive Innovation Fund, known for its application of the theory of Disruptive Innovation® developed by co-founder Clayton Christensen. Terms of the investment were not released.
“This strategic investment from Rose Park Advisors underscores the ability of Norsk Titanium’s Rapid Plasma Deposition™ (RPD™) technology to disrupt the metal manufacturing processes,” said Norsk Titanium Chairman of the Board John Andersen, Jr. “There are few people that are as widely respected by more business leaders than Dr. Christensen. We are humbled by his recognition of our technology and business model.”
“Our strong relationships in commercial aerospace have allowed us to improve our processes and create a platform technology under the watchful eyes of the most-regulated of all sectors.” Mr. Andersen continued, “This allows Norsk Titanium to pursue its ambition to provide access to its RPD™ technology in the commercial aerospace sector and beyond. By bringing our customers unprecedented application opportunities, we hope to accelerate revolutionary changes to the world’s metal manufacturing processes.”
“Although people use the term casually and most start-ups believe they are disruptive, very few, in fact, have the right business model in the right circumstances to achieve disruptive success,” said Matt Christensen, co-founder and Managing Partner of Rose Park Advisors. “Norsk Titanium has identified a truly disruptive opportunity. Seeing our research in action is always exciting, and to see it in metals manufacturing – where one of the classic historical examples of disruption occurred – is even better. We’re very excited to be working to help Norsk Titanium achieve its full potential.”
Dr. Om Nalamasu, CTO of Applied Materials and President of Applied Ventures, added, “The high-tech sector has been defined by the views and insight of Dr. Christensen, and we welcome recognition of Norsk Titanium’s RPD™ technology for its disruptive tenets.”
Jeremy Barnes, a partner in Triangle Holdings, an aerospace investment company owned by funds managed by affiliates of Fortress Investment Group, echoes the sentiment, “We are fortunate to partner with Rose Park Advisors in this most exciting venture.”
In October 2017, Boeing started the delivery of aircraft into commercial service which contained additive manufactured Ti64 structural aviation components produced by RPD™ technology - yet another landmark in the aerospace sector for Norsk Titanium’s FAA certified, 3D-printing process. Earlier in October, Governor Andrew M. Cuomo announced that Norsk Titanium has begun operations for future production of components for Boeing and Spirit AeroSystems at the world’s first industrial scale metal additive manufacturing plant in Plattsburgh, New York.
About Norsk Titanium AS
Norsk Titanium AS is the world’s pioneering supplier of aerospace-grade, additive manufactured, structural titanium components. The company is distinguished in the aviation industry by its patented Rapid Plasma Deposition™ (RPD™) process that transforms titanium wire into complex components suitable for structural and safety-critical applications. The Norsk Titanium research and development team is committed to displacing the inefficient forging and machining processes with a precision wire deposition technology enabling substantial savings for aerospace, defense, and commercial applications. To learn more, please visit www.norsktitanium.com.
About Rose Park Advisors LLC
Rose Park Advisors is a specialized investment firm that applies the theory of Disruptive Innovation® developed by co-founder Clayton Christensen to invest in companies whose business models are well-suited to take advantage of industry change. Rose Park Advisors pursues disruptive opportunities across industries, geographies, and company size and stage. To learn more, please visit www.roseparkadvisors.com.
Griffin Communications Group
Lauren Quesada, 281-744-7938
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00 | Tiedote
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo
Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 201821.5.2018 12:44 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. “The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current stand
STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00 | Tiedote
Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,
Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00 | Tiedote
Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme